<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407602</url>
  </required_header>
  <id_info>
    <org_study_id>CP-003-001</org_study_id>
    <secondary_id>National Eye Institute (NEI)</secondary_id>
    <nct_id>NCT00407602</nct_id>
  </id_info>
  <brief_title>Argus® II Retinal Stimulation System Feasibility Protocol</brief_title>
  <official_title>Argus® II Retinal Stimulation System Feasibility Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Sight Medical Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Sight Medical Products</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this feasibility study is to evaluate the safety and utility of the Argus II
      Retinal Stimulation System in providing visual function to blind subjects with severe to
      profound retinitis pigmentosa.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orientation and Mobility</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spatial Vision</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of Implant</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>System Functionality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Implant of Argus II Retinal Prosthesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Argus II Retinal Stimulation System</intervention_name>
    <description>epiretinal implantation of device</description>
    <arm_group_label>Implant of Argus II Retinal Prosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A confirmed history of retinitis pigmentosa (all centers) or outer retinal
             degeneration (France, U.K., Switzerland, Mexico only) with remaining visual acuity of
             bare light perception (all centers) or 2.3 logMAR (France, U.K., Switzerland, Mexico
             only) or worse in both eyes.

          -  Functional ganglion cells and optic nerve as determined by a measurable electrically
             evoked response or documented light perception.

          -  A history of former useful form vision in the worse-seeing eye.

          -  Must be at least the following age at the time of enrollment: 25 (USA, Switzerland) or
             18 (France, U.K., and Mexico) years old

          -  Must reside within 2 hours (USA, UK and Mexico) or 3 hours (France and Switzerland)
             distance (by ground transportation) of the investigational site.

          -  Must be willing and able to comply with the protocol testing and follow-up
             requirements.

        Exclusion Criteria:

          -  Optic Nerve disease

               -  History of glaucoma

               -  Optic neuropathy or other confirmed damage to optic nerve or visual cortex damage

          -  Diseases or conditions that effect retinal function including but not limited to:

               -  Central retinal artery/vein occlusion (CRAO or CRVO)

               -  End-stage diabetic retinopathy

               -  Retinal detachment or history of retinal detachment

               -  Trauma

               -  Infectious or inflammatory retinal diseases

          -  Diseases or conditions that prevent adequate visualization of the retina including,
             but not limited to corneal degeneration that cannot be resolved before implant.

          -  Diseases or conditions of the anterior segment that prevent the ability to adequately
             perform the physical examination including but not limited to trauma or lid
             malpositions.

          -  Diseases of the ocular surface including but not limited to keratitis sicca.

          -  An ocular condition that predisposes the subject to eye rubbing.

          -  Any disease or condition that prevents understanding or communication of informed
             consent, study demands, and testing protocols, including:

               -  Cognitive decline including diagnosed forms of dementia and/or progressive
                  neurological disease

               -  Psychiatric Disease including diagnosed forms of depression

               -  Does not speak a principal language associated with the region

               -  Deafness or selective frequency hearing loss that prevents hearing device alarms
                  and alerts.

          -  Pregnancy

          -  Subject has another active implantable device (e.g. cochlear implant), or any form of
             metallic implant in the head

          -  Conjunctival thinning which may predispose the subject to conjunctival erosion in the
             area where the implant will be installed extra-ocularly.

          -  Subject is participating in another investigational drug or device study that may
             conflict with the objectives, follow-up or testing of this study

          -  Any health concern that makes general anesthesia inadvisable.

          -  Subject has unrealistic expectations of the implant.

          -  Known allergy or contraindication to anticipated pre-operative, intra-operative or
             post-operative medications.

          -  Conditions likely to limit life to less than 1 year from the time of screening.

          -  Diseases or conditions that, in the judgement of the surgeon, impede the ability to
             implant the device or would prevent the system from functioning for the duration of
             the study (e.g. strabismus)

          -  Axial eye length &lt;21.5 mm or &gt;26.0 mm in the implanted eye as measured by ultrasound
             (US only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Marie Ripley</last_name>
    <role>Study Director</role>
    <affiliation>Second Sight Medical Products</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Doheny Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins, Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Scheie Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerta de Hierro, Centro Medico, Centro de Retina</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>51116</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital, Vitreoretinal Research Unit</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Mexico</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weiland JD, Faraji B, Greenberg RJ, Humayun MS, Shellock FG. Assessment of MRI issues for the Argus II retinal prosthesis. Magn Reson Imaging. 2012 Apr;30(3):382-9. doi: 10.1016/j.mri.2011.12.005. Epub 2012 Jan 20.</citation>
    <PMID>22260934</PMID>
  </reference>
  <results_reference>
    <citation>Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, Cideciyan AV, Duncan JL, Eliott D, Filley E, Ho AC, Santos A, Safran AB, Arditi A, Del Priore LV, Greenberg RJ; Argus II Study Group. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012 Apr;119(4):779-88. doi: 10.1016/j.ophtha.2011.09.028. Epub 2012 Jan 11.</citation>
    <PMID>22244176</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiddes TM, Monk NA, Hashish AF, Richards BJ, Bardwell LM, Watt AJ, Gardner RJ. Early prenatal diagnosis of genetic abnormality by chorion villus sampling. N Z Med J. 1990 Apr 11;103(887):157-8.</citation>
    <PMID>2342673</PMID>
  </results_reference>
  <results_reference>
    <citation>Barry MP, Dagnelie G; Argus II Study Group. Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. Invest Ophthalmol Vis Sci. 2012 Aug 1;53(9):5095-101. doi: 10.1167/iovs.12-9536.</citation>
    <PMID>22661464</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahuja AK, Dorn JD, Caspi A, McMahon MJ, Dagnelie G, Dacruz L, Stanga P, Humayun MS, Greenberg RJ; Argus II Study Group. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. 2011 Apr;95(4):539-43. doi: 10.1136/bjo.2010.179622. Epub 2010 Sep 29.</citation>
    <PMID>20881025</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retinitis pigmentosa</keyword>
  <keyword>device</keyword>
  <keyword>retinal implant</keyword>
  <keyword>retinal prosthesis</keyword>
  <keyword>RP</keyword>
  <keyword>outer retinal degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

